Using knowledge of matrix biology and lung development, what are useable methods to modify cadaveric donor lungs to provide a durable, effective organ replacement therapy?

What are the biological properties and key surface markers of human lung progenitor cells and lung epithelial differentiated iPSCs? How can these cell populations be targeted for therapeutic purposes, including regenerative therapy?